MI HB4298

Requires physicians to provide patients with written informed consent before performing cosmetic breast implant surgery, effective January 1, 2026

Mandates disclosure of breast implant risks, surgical procedure descriptions, FDA warning requirements, and manufacturer patient information materials at the initial consultation

Directs the medical board to develop an informed consent checklist by December 31, 2025, covering breast implant-associated cancers (including anaplastic large cell lymphoma, squamous cell carcinoma, and B-cell lymphoma) and breast implant illness

Requires the checklist to include a statement that the FDA has issued a black box warning on breast implant packaging and information about the National Breast Implant Registry

Mandates providing patients with information on how to report adverse events through the FDA's medical product safety reporting program